34777679|PMC8575483
{'Chemical', 'Disease', 'Species', 'Gene'}
Vaccination against viral and bacterial pathogens represents a challenging issue in allergic subjects, mainly concerning patients undergoing allergen immunotherapy (AIT). In this regard, Ulrich and colleagues analysed the data of 875 patients receiving subcutaneous immunotherapy (SCIT) and/or vaccination. Finally, the COVID-19 pandemic induced to think about the safety of AIT products.